# Reverb Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reverb-therapeutics

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.reverbtx.com
- Total disclosed funding: $12M
- Latest round: Seed (Feb 19, 2025)
- Investors on record: 6

## About

Reverb Therapeutics Inc. is a biotechnology company focused on the innovative development of bispecific antibodies that leverage the natural immune system to enhance therapeutic outcomes for various diseases. Reverb Therapeutics Inc. was founded in 2023 in Vancouver, Canada, and specializes in creating bispecific antibodies for therapeutic applications. In February 2025, Reverb Therapeutics Inc. raised USD 12 million in seed funding led by Amplitude, with participation from Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, InBC Investment, and Seido Capital. This funding will help advance their lead IL-15 bispecific program and further develop additional bispecific programs. Reverb Therapeutics specializes in the development of bispecific antibodies that harness the therapeutic potential of the natural immune system. Their core product offerings revolve around the Amplify·R platform, which is designed to amplify natural cytokine signaling, aiming to enhance immune responses for diverse therapeutic applications. The primary use cases these products aim to address include various malignancies and autoimmune diseases, with a focus on improving patient outcomes through innovative treatment modalities. The company serves a range of stakeholders in the biopharmaceutical sector, with potential end users including healthcare providers and patients suffering from conditions that require enhanced immune interventions. Reverb Therapeutics targets markets that span North America and Europe, focusing on regions with advanced healthcare infrastructures and active biopharmaceutical research initiatives.Reverb Therapeutics' revenue generation model is primarily based on partnerships and collaborations with other biopharmaceutical entities, leveraging their research and development capabilities. Transactions typically occur through strategic alliances that may include co-development agreements, licensing deals, and research collaborations, allowing them to monetize their proprietary technologies. The company’s offerings, particularly the bispecific antibodies developed through the Amplify·R platform, are poised to attract interest from pharmaceutical companies seeking to enhance their product pipelines. Specific pricing plans and financial structures related to their products and services are not disclosed, but the nature of these partnerships suggests a focus on milestone payments and potential royalties based on the commercialization success of their therapeutic innovations. Reverb Therapeutics plans to utilize the recent funding of USD 12.00 mn raised in February 2025 to advance its lead IL-15 bispecific program to the candidate stage and to develop additional bispecific programs targeting other cytokines and cellular targets. The company is focused on launching new products designed to enhance immune responses, thereby addressing critical healthcare needs. Reverb is also exploring expansions into additional markets across North America and Europe by the end of 2025, aiming to strengthen their presence in regions with robust biopharmaceutical research activities.

## Funding rounds

- Seed, Feb 19, 2025, $12M — InBC Investment, Seido Capital, KdT Ventures, Amplitude, Myeloma Investment Fund, Finchley Healthcare Ventures

## Investors

- InBC Investment — Seed
- Seido Capital (https://capitalatlas.ai/funds/seido-capital) — Seed
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Seed
- Amplitude (https://capitalatlas.ai/funds/amplitude) — Seed
- Myeloma Investment Fund (https://capitalatlas.ai/funds/myeloma-investment-fund) — Seed
- Finchley Healthcare Ventures (https://capitalatlas.ai/funds/finchley-healthcare-ventures) — Seed